Paul Hudson

Paul Hudson

executive France

Paul Hudson is the Chief Executive Officer of Sanofi, a global biopharmaceutical company. Under his leadership, Sanofi has made significant investments in China, particularly in biopharmaceutical manufacturing and innovation, including a recent €1 billion investment to expand its production capacity in the Beijing Economic-Technological Development Area. Hudson's commitment to enhancing healthcare solutions aligns with the growing demand for diabetes treatments and advanced medical technologies.

Born on Jan 01, 1967 (58 years old)

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
28
Power
5$
Sentiment
6.00
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
Liechtenstein 1 6.00 0.07% +0% 38,137 28 $6,900 5$
Totals 1 38,137 28 $6,900 5$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Serbia Serbia: Paul Hudson is the CEO of Sanofi and commented on the strategic importance of the acquisition of Bluprint. 8

Blic – popular Serbian tabloid/daily, est. 1996: Sanofi kupuje američku biotehnološku kompaniju Bluprint za 9,1 milijardu dolara

Monaco Monaco: Paul Hudson, CEO of Sanofi, stated that the acquisition represents a strategic leap forward in their rare diseases and immunology portfolios. 8

Monaco-Matin – newspaper covering the Principality of Monaco: Sanofi acquiert la biotech américaine Blueprint pour 9,1 milliards de dollars

Turkey Turkey: Paul Hudson is the President of FlyersRights who criticizes the lack of seat size adjustments in airlines despite increasing passenger sizes. 6

Hürriyet: Uçak koltukları neden bu kadar küçük? Mesafe mi azaldı yolcular mı büyüdü? | Her şey 1978'de başladı...

Switzerland Switzerland: Paul Hudson, the CEO of Sanofi, joined Vas Narasimhan in addressing the need for higher medication prices in Europe. 6

Neue Zürcher Zeitung: Schweiz soll höhere Preise für Medikamente bezahlen

Slovenia Slovenia: Paul Hudson, the CEO of Sanofi, warns that low drug prices and bureaucracy in Europe are making the region less attractive for pharmaceutical investments. 6

Delo – major Slovenian daily, est. 1959: Novartis in drugi farmacevtski velikani pozivajo k višjim cenam zdravil v EU